Allan Young
Professor of Psychiatry
Data updated
Research Footprint
Allan Young appears in 21 tracked papers (2016–2026), most studied alongside Psilocybin, Ketamine and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: James Rucker, Luke Jelen and Guy Goodwin.
Publication Landscape
How the 21 papers Blossom tracks for Allan Young line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Allan Young's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 21 of 21 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Allan Young publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Allan Young publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Allan H. Young is a psychiatrist and academic whose work spans mood disorders, psychopharmacology and translational clinical research. He has led and contributed to a range of clinical studies and reviews examining rapid-acting antidepressants and psychedelic compounds, with particular emphasis on treatment‑resistant depression, neuroimaging correlates of treatment response, and the safety and tolerability of novel interventions. He has been an investigator on randomized and feasibility trials (including protocols for psilocybin-assisted therapy), phase‑1 studies of intranasal DMT formulations, and secondary analyses comparing esketamine with other pharmacotherapies in treatment‑resistant depression. He has also contributed to syntheses of the evidence base for ketamine and esketamine and to reviews of classical psychedelics such as ayahuasca.
Key Impact
A senior clinical psychiatrist and researcher who has helped translate psychedelic and rapid-acting psychopharmacological interventions into clinical research for treatment-resistant mood disorders.
Collaboration Network
61 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Allan Young's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Allan Young is associated with.
Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways plc (Nasdaq: CMPS) is a UK-headquartered clinical-stage biopharmaceutical company and the most advanced developer of a classic psychedelic medicine. Its lead asset, COMP360 — a synthetic, proprietary formulation of psilocybin — is being developed for treatment-resistant depression (TRD) delivered alongside a psychological-support model. COMP360 is the first psilocybin programme to complete two positive pivotal Phase 3 trials: COMP005 met its primary endpoint in June 2025 and the confirmatory COMP006 (two fixed doses given three weeks apart) did so in February 2026, with 26-week data reported in July 2026 confirming a rapid and durable antidepressant profile. In April 2026 the FDA granted a rolling NDA submission request and selected COMP360 for the Commissioner's National Priority Voucher programme, which carries a shortened review window. COMPASS has since begun that rolling submission and guides to a potential US launch in the first half of 2027, subject to approval, positioning it as the frontrunner for the first FDA-approved classic psychedelic therapy.
View stakeholder →